These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17187139)

  • 61. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.
    Wirtschafter JD; McLoon LK
    Ophthalmology; 1998 Feb; 105(2):342-6. PubMed ID: 9479297
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
    Drummond GT; Hinz BJ
    Can J Ophthalmol; 2001 Dec; 36(7):398-403. PubMed ID: 11794389
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparison of facial muscle squeezing versus non-facial muscle squeezing on the efficacy of botulinumtoxin-A injections for the treatment of facial dystonia.
    O' Reilly P; Ross J; Norris J; Malhotra R
    Orbit; 2012 Dec; 31(6):400-3. PubMed ID: 23061606
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
    Karp BI; Alter K
    Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Botulinum Toxins for Treating Essential Blepharospasm and Hemifacial Spasm.
    Ozzello DJ; Giacometti JN
    Int Ophthalmol Clin; 2018; 58(1):49-61. PubMed ID: 29239877
    [No Abstract]   [Full Text] [Related]  

  • 66. Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm.
    Romero-Caballero MD; Miralles de Imperial-Ollero JA; Sarabia-Marín E; Villegas-Pérez MP
    Int Ophthalmol; 2023 Aug; 43(8):2731-2736. PubMed ID: 37185774
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm.
    Price J; O'Day J
    Aust N Z J Ophthalmol; 1994 Nov; 22(4):255-60. PubMed ID: 7727103
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Safety and efficacy of botulinum toxin in hemifacial spasm].
    Mazlout H; Kamoun Gargouri H; Triki W; Kéfi S; Brour J; El Afrit MA; Chéour M; Kraiem A
    J Fr Ophtalmol; 2013 Mar; 36(3):242-6. PubMed ID: 23270989
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preseptal and Pretarsal Botulinum Toxin Injection in Hemifacial Spasm and Blepharospasm: A 10-Year Comparative Study.
    Teekaput C; Teekaput K; Thiankhaw K
    Ther Clin Risk Manag; 2023; 19():35-42. PubMed ID: 36660550
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anesthesia with EMLA cream for botulinum A toxin injection into eyelids.
    Söylev MF; Koçak N; Kuvaki B; Ozkan SB; Kir E
    Ophthalmologica; 2002; 216(5):355-8. PubMed ID: 12424403
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of dietary zinc and phytase supplementation on botulinum toxin treatments.
    Koshy JC; Sharabi SE; Feldman EM; Hollier LH; Patrinely JR; Soparkar CN
    J Drugs Dermatol; 2012 Apr; 11(4):507-12. PubMed ID: 22453589
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Botulinum toxin in the treatment of facial dystonia: evaluation of its efficacy and patients' satisfaction along the treatment].
    Costa PG; Aoki L; Saraiva FP; Matayoshi S
    Arq Bras Oftalmol; 2005; 68(4):471-4. PubMed ID: 16322831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?].
    Roggenkämper P
    Ophthalmologe; 2007 Sep; 104(9):763-6. PubMed ID: 17726608
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm.
    Osaki MH; Osaki TH; Garcia DM; Osaki T; Gameiro G; Belfort R; Cruz AAV
    Eur J Neurol; 2020 Aug; 27(8):1487-1492. PubMed ID: 32294304
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Botulinum toxin A: experience in the treatment of 115 patients].
    Andrade LA; Borges V; Ferraz HB; Azevedo-Silva SM
    Arq Neuropsiquiatr; 1997 Sep; 55(3B):553-7. PubMed ID: 9629404
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases.
    Ortisi E; Henderson HW; Bunce C; Xing W; Collin JR
    Eye (Lond); 2006 Aug; 20(8):916-22. PubMed ID: 16531977
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin.
    Gil Polo C; Rodríguez Sanz MF; Berrocal Izquierdo N; Castrillo Sanz A; Gutiérrez Ríos R; Zamora García MI; Mendoza Rodríguez A; Duarte García-Luis J
    Neurologia; 2013 Apr; 28(3):131-6. PubMed ID: 22652139
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A new grading system for assessing orbicularis muscle function.
    Rahman R; Berry-Brincat A; Thaller VT
    Eye (Lond); 2003 Jul; 17(5):610-2. PubMed ID: 12855968
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Periorbital injections of botulinum toxin a: a novel therapeutic option for convergence spasm in neuropsychiatric disorders.
    Hess K; Schmitt M; Wabbels B
    J Neurol; 2022 Jan; 269(1):243-250. PubMed ID: 34047854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.